Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine

ABSTRACT

Introduction: Enterovirus A71 (EV71) is the predominant causative agent of hand, foot, and mouth disease (HFMD), which is often associated with severe cases and even deaths. EV71-associated epidemics have emerged as a serious threat to public health, particularly in the Asia-Pacific region.

Areas covered: We searched PubMed using the terms ‘enterovirus 71’, ‘hand, foot, and mouth disease’, and ‘vaccine’, with no date or language restrictions for all publications before April 27, 2016. Among various vaccine candidates, the alum-adjuvant inactivated EV71 vaccines are most promising. Three alum-adjuvant inactivated EV71 vaccines developed by mainland China showed high efficacy, good immunogenicity persistence and acceptable safety profiles in clinical trials. Recently, two of these EV71 vaccines have been approved for marketing in China and the other one is undergoing the review process of licensure. In this manuscript, we summarized previous study results as well as discussed the regulatory affairs and post-market surveillances issues.

Expert commentary: The marketing of EV71 vaccines is a milestone in the controlling of HFMD. International clinical trials are needed to further assess the efficacy and cross-immunogenicity. Establishing a sensitive pathogen monitoring system would be essential to monitor the variation of genotypes and control HFMD epidemics.

KEYWORDS:

• Enterovirus A71 vaccine
• hand
• foot
• and mouth disease
• clinical trial
• efficacy
• immunogenicity
• safety
• cross-immunity
• surrogate of protection

Declaration of interest

This work was supported by the Fundamental Research Funds for the Central Universities (No. SJZZ_0036). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.